Skip to main content

Pharma/Regulatory

Best of 2024: Pain Reduction with Methotrexate in Knee Osteoarthritis

The Annals of Internal Medicine reports that oral, low dose, weekly methotrexate significantly reduced knee osteoarthritis pain, stiffness, and function in a randomized controlled trial.

Read Article
Abuse of the Safety-Net 340B Drug Programs Dr. Madelaine Feldman comments on the 340B Drug Pricing Program, a safety-net initiative designed to provide costly therapies to vulnerable populations. She argues that the program has deviated from its original intent, with certain… https://t.co/5rIQHsIeAS https://t.co/rXwQPctHDf
Dr. John Cush @RheumNow( View Tweet )

Best of 2024: Analgesic Prescribing in Patients with Inflammatory Arthritis

A UK cross-sectional EHR clinical practice analysis between 2004 and 2020 shows that analgesic prescribing in inflammatory arthritis patients has declined, but still remains substantial, including opioid prescribing. Data was drawn from the Clinical Practice Research Datalink Aurum to evaluate

Read Article

Bah Humbug Vitamin D (12.20.2024)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
ICYMI: JAKi in inflammatory myositis? #ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis… https://t.co/8XOYOsDsD4 https://t.co/MF0EGO0BJz
Dr. John Cush @RheumNow( View Tweet )
3 biosimilars from Celltrion have received a positive recommendatoin from the CHMP of the EMA for pt), Stoboclo and Osenvelt (denosumab biosimilars), and Avtozma (tocilizumab biosimilar), possibly redefining treatment affordability and accessibility across Europe.… https://t.co/dYXfUSpP5I https://t.co/wLQMXomoVS
Dr. John Cush @RheumNow( View Tweet )
ICYMI: Are Emulation Trials a Fantasy? https://t.co/eCO8a1UFlB https://t.co/PPczmxYFKa
Dr. John Cush @RheumNow( View Tweet )

Abuse of the Safety-Net 340B Drug Programs

Dr. Madelaine Feldman has written an important commentary on the 340B Drug Pricing Program, a safety-net program that would allow vulnerable populations to receive expensive new therapies. But she points out that "this well-intentioned program has strayed from its original purpose", allowing

Read Article

Tocilizumab Efficacy in Giant Cell Arteritis Phenotypes

A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated. 

Multicentre study of 471 GCA patients treated with TCZ, assessed outcomes according to vascular

Read Article

Biosimilars Do Impact Biologic Drug Costs

MedPage Today

Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these products -- even though biosimilars barely dented Humira prescription rates.

Read Article

54K Peptic Ulcers Annually (12.13.2024)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Read Article

Safety of Acetaminophen in the Elderly

EurekAlert!

New research, led by experts at the University of Nottingham, has found that repeated doses of paracetamol in people aged 65 and over, can lead to an increased risk of gastrointestinal, cardiovascular and renal complications.

The new study, which is published in

Read Article

Treat-to-Target LLDAS in Lupus

MedPage Today

Patients with highly active systemic lupus erythematosus (SLE) appeared to sustain much less organ damage and fewer disease flares when drug therapy yielded substantial relief, researchers found.

Unfortunately, only a minority of such patients achieved low disease activity or remission

Read Article

Drug-Free Remission in Giant Cell Arteritis is Uncommon

A Spanish retrospective registry study of patients with giant cell arteritis (GCA) found that 3-4 years after diagnosis, only 21% of patients with GCA successfully reached the sustained drug-free remission (SDFR). But if SDFR was achieved, the likelihood of experiencing recurrence was

Read Article

Way Behind in Pediatric Rheumatology

While adult rheumatology fellowships have surged in popularity and become quite competitive, more than half of pediatric rheumatology fellowship positions went unfilled in 2024, according to the National Resident Matching Program (NRMP). 

According to Medscape, across all 39

Read Article
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/SMKx1LnBB1 https://t.co/96u5YuvyIf
Dr. John Cush @RheumNow( View Tweet )
Ozempic will change rheumatology @drdavidliew Ozempic is everywhere. Even all the way in Australia, where we have highly constrained supply that makes headlines and substantial limits on direct-to-consumer advertising, somehow I know the jingle from the American ad for Ozempic.… https://t.co/4gujykjDCa https://t.co/RLG1vA57kC
Dr. John Cush @RheumNow( View Tweet )

Don’t Buy Guitars (12.6.2024)

This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.

Read Article

Challenge in Measuring Cutaneous Lupus Activity and Severity

JAMA Dermatology features a discussion by Drs. McMichael and Frey on measuring lupus skin disease in clinical trials and practice using the validated Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI).

Read Article
ICYMI: Shifting Trends in Initial RA Treatment Approaches A recent study by Sparks et al (Abstract #0509) reveals evolving trends in disease-modifying antirheumatic drug (DMARD) usage for RA over two decades in the US. https://t.co/XlMXkuBBVN https://t.co/AHi3DG0aFV https://t.co/vNLF4Ft1GR
Dr. John Cush @RheumNow( View Tweet )
UK study compared 16,634 female RA pts vs 65,448 controls and found all RA women at incr risk for VTE (thrombosis)[aHR=1.52) irrespective of estrogen contraceptives/HRT. Contraceptives did not increase VTE risk (aHR 2.32; 0.92, 5.85, p=0.08) #ACR24 https://t.co/AzBXI0W5dv https://t.co/Q4TaKq2ReC
Dr. John Cush @RheumNow( View Tweet )
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/ASErsKTNQ6 https://t.co/d1BRW92vju
Dr. John Cush @RheumNow( View Tweet )
Ozempic will change rheumatology @drdavidliew Ozempic is everywhere. Even all the way in Australia, where we have highly constrained supply that makes headlines and substantial limits on direct-to-consumer advertising, somehow I know the jingle from the American ad for Ozempic.… https://t.co/lELDs7Yy5W https://t.co/wuXZR4vkx8
Dr. John Cush @RheumNow( View Tweet )
Cyclophosphomide vs Mycophenolate vs Tacrolimus in Lupus Nephritis Dr. Mike Putman discusses abstract 0670, presented at #ACR24. https://t.co/aLzsSSOmML https://t.co/XrEtNZAgHI
Dr. John Cush @RheumNow( View Tweet )
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. Content is chosen by RheumNow & its facult.y

Dr. John Cush @RheumNow( View Tweet )

×